Acolbifene
- Generic Name
- Acolbifene
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H31NO4
- CAS Number
- 182167-02-8
- Unique Ingredient Identifier
- 815LJ9X0D1
- Background
Acolbifene is under investigation in clinical trial NCT01452373 (Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women).
- Associated Conditions
- -
- Associated Therapies
- -
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Breast Atypical HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In SituBreast Lobular Carcinoma In Situ
- Interventions
- Drug: Acolbifene HydrochlorideProcedure: Biospecimen CollectionProcedure: MammographyProcedure: Random Periareolar Fine-Needle AspirationDrug: Tamoxifen
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT05941520
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Kansas Cancer Center, Kansas City, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath